Berg, Thomas

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

Update of the statements on biology and clinical impact of occult hepatitis B virus infection

Raimondo, G., Locarnini, S., Pollicino, T., Levrero, M., Zoulim, F., Lok, A. S., Allain, J.-P., Berg, T., Bertoletti, A., Brunetto, M. R., et al. (2019) · Journal of Hepatology

Hepatitis B Virus StudiesHepatitis C virus research

Cited by 572

A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis

Buch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics

Alcohol Consumption and Health EffectsGenetic Associations and Epidemiology

Cited by 565

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

Boettler, T., Newsome, P. N., Mondelli, M. U., Maticic, M., Cordero, E., Cornberg, M., & Berg, T. (2020) · JHEP Reports

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 477

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 469

Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis

Rosendahl, J., Witt, H., Szmola, R., Bhatia, E., Ózsvári, B., Landt, O., Schulz, H.-U., Gress, T. M., Pfützer, R., Löhr, M., et al. (2008) · Nature Genetics

Pancreatitis Pathology and TreatmentPancreatic and Hepatic Oncology Research

Cited by 439

Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores

Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentGenetic Associations and Epidemiology

Cited by 385

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Sangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 365

High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial†

Leuschner, U. F. H., Lindenthal, B., Herrmann, G., Arnold, J. C., Rössle, M., Cordes, H., Zeuzem, S., Hein, J., & Berg, T. (2010) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 317

Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1

de Boer, Y. S., van Gerven, N. M. F., Zwiers, A., Verwer, B. J., van Hoek, B., van Erpecum, K. J., Beuers, U., van Buuren, H. R., Drenth, J. P. H., den Ouden, J. W., et al. (2014) · Gastroenterology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 304

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., et al. (2021) · Nature Medicine

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 222

Loss of hepatic Mboat7 leads to liver fibrosis

Thangapandi, V. R., Knittelfelder, O., Brosch, M., Patsenker, E., Vvedenskaya, O., Buch, S., Hinz, S., Hendricks, A., Nati, M., Herrmann, A., et al. (2021) · Gut

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 125

Intrahepatic cholestasis in common chronic liver diseases

Jüngst, C., Berg, T., Cheng, J., Green, R. M., Jia, J., Mason, A. L., & Lammert, F. (2013) · European Journal of Clinical Investigation

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 82

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis

Soret, P., Lam, L., Carrat, F., Smets, L., Berg, T., Carbone, M., Invernizzi, P., Leroy, V., Trivedi, P., Cazzagon, N., et al. (2021) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 78

Pregnancy in primary sclerosing cholangitis

Wellge, B. E., Sterneck, M., Teufel, A., Rust, C., Franke, A., Schreiber, S., Berg, T., Günther, R., Kreisel, W., zu Eulenburg, C., et al. (2011) · Gut

Liver Diseases and ImmunityPregnancy and Medication Impact

Cited by 76

Increased Level of Interleukin 6 Associates With Increased 90-Day and 1-Year Mortality in Patients With End-Stage Liver Disease

Remmler, J., Schneider, C., Treuner-Kaueroff, T., Bartels, M., Seehofer, D., Scholz, M., Berg, T., & Kaiser, T. (2018) · Clinical Gastroenterology and Hepatology

Liver Disease and TransplantationSepsis Diagnosis and Treatment

Cited by 56